Results 191 to 200 of about 240,433 (353)

Gene signatures characterizing driver mutations in lung squamous carcinoma are predictive of the progression of pre‐cancer lesions

International Journal of Cancer, EarlyView.
What's New? Lung squamous cell carcinoma (LUSC) is more aggressive than lung adenocarcinoma, and is most often diagnosed at an advanced stage. Here, the authors evaluated gene expression data from LUSC tumors and came up with gene signatures for 34 genetic abnormalities whose expression changes throughout different precancerous stages. Several of these
Yupei Lin, Venugopalareddy Mekala, Jianrong Li, Xiang Wang, Muhammad Aminu, Jia Wu, Jianjun Zhang, Robert Taylor Ripley, Christopher I. Amos, Chao Cheng   +9 more
wiley   +1 more source

Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML. [PDF]

Blood Adv
Baeten JT, Agashe S, Tabet I, Wooldridge JT, Carter A, Butler JN, Miller CA, Helton N, Quinet A, Johansson KB, Yang Y, Uy GL, Vindigni A, Link DC.   +13 more
europepmc   +1 more source

KMT2D and TP53 mutation status improve the prognostic value of the International Prognostic Index (IPI) stratification in ENKTL patients

, 2020
Yuhua Gao, Yong Li, Guansheng Ma, Guoping Zhao, H. LIU   +4 more
openalex   +2 more sources

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen [PDF]

, 2003
Jolanta Kupryjańczyk, T Szymańska, Radosław Mądry, Agnieszka Timorek, J Stelmachów, G Karpińska, Alina Rembiszewska, I Ziółkowska, Ewa Kraszewska, Jarosław Dębniak, Janusz Emerich, Małgorzata Ułańska, A Płużańska, Marcin Jędryka, M Goluda, Anita Chudecka-Głaz, I Rzepka-Górska, Małgorzata Klimek, Krzysztof Urbański, J Bręborowicz, J Zieliński, Janina Markowska   +21 more
openalex   +1 more source

Prediction of the individual risk for the development of brain metastases in patients with non‐oncogene‐addicted non‐small cell lung cancer: Real‐world data from the German prospective CRISP registry (AIO‐TRK‐0315)

International Journal of Cancer, EarlyView.
What's New? Estimating the risk of developing brain metastases may enable earlier diagnosis and treatment, potentially reducing morbidity and mortality. Using the prospective CRISP lung cancer registry, the authors developed and validated a point‐based classifier for the risk of developing first brain metastases in patients with advanced or metastatic ...
Fabian Acker, Katharina Wenger, Martin Reck, Cornelius F. Waller, Petra Hoffknecht, Andre Bethge, Arnd Nusch, Marcel Reiser, Christiane Bernhardt, Michael Bendel, Carolin Lennartz, Annette Fleitz, Martina Jänicke, Paula Ludwig, Annika Groth, Frank Griesinger, Michael Thomas, Wilfried E. E. Eberhardt, Martin Sebastian, for the CRISP Registry Group   +19 more
wiley   +1 more source

Low-penetrance TP53 variants are mainly hypomorphic: an underestimated issue with high clinical significance. [PDF]

NPJ Genom Med
Rodriguez L, Leroy B, Toledo F, Funk JS, Stiewe T, Baliakas P, Delhommeau F, Soussi T.   +7 more
europepmc   +1 more source

TP53

Oncology Times, 2019
openaire   +2 more sources

Globo‐H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer

International Journal of Cancer, EarlyView.
What's New? Colorectal cancer (CRC) is increasingly complicated by drug‐resistant tumors that limit the effectiveness of anticancer therapies. Because resistance mechanisms vary among patients and can evolve over time, personalized treatment strategies are needed.
Keren Zohar, Marco Strecker, Thomas Wartmann, Wenjie Shi, Frederike Stelter, Maximilian Doelling, Mihailo Andric, Or Kakhlon, Christian Täger, Denny Schanze, Michael Linnebacher, Michael Naumann, Daniel E. Stange, Dörthe Jechorek, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Unraveling the role of <i>TP53</i> mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation. [PDF]

Hemasphere
da Silva-Benedito S, Bernardo PS, Martin JE, Marty C, Plo I, Antony-Debré I, Monte-Mór BDCR.   +6 more
europepmc   +1 more source